

Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma

James A Richter, Michel Kahaleh

James A Richter, Michel Kahaleh, University of Virginia Health System, Charlottesville, VA 22908-0708, United States

Author contributions: Both Richter JA and Kahaleh M wrote and edited all portions of this manuscript; and Kahaleh M came up with the concept of the paper.

Correspondence to: Michel Kahaleh, MD, Director, Pancreatico-Biliary Services, Digestive Health Center Box 800708, University of Virginia Health System, Charlottesville, VA 22908-0708, United States. mk5ke@virginia.edu

Telephone: +1-434-2439259 Fax: +1-434-9240491

Received: June 3, 2010 Revised: August 25, 2010

Accepted: September 1, 2010

Published online: November 16, 2010

Abstract

Cholangiocarcinoma is the primary malignancy arising from the biliary epithelium. The disease is marked by jaundice, cholestasis, and cholangitis. Over 50 percent of patients present with advanced stage disease, precluding curative surgical resection as an option of treatment. Prognosis is poor, and survival has been limited even after biliary decompression. Palliative management has become the standard of care for unresectable disease and has evolved to include an endoscopic approach. Photodynamic therapy (PDT) consists of administration of a photosensitizer followed by local irradiation with laser therapy. Several studies conducted in Europe and the United States have shown a marked improvement in the symptoms of cholestasis, survival, and quality of life. This article summarizes the published experience regarding PDT for cholangiocarcinoma and the steps required to administer this therapy safely.

© 2010 Baishideng. All rights reserved.

Key words: Cholangiocarcinoma; Cholestasis; Jaundice; Neoplasia; Palliation; Photodynamic therapy; Photofrin

Peer reviewer: Omar Javed Shah, Professor, Head, Department of Surgical Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India

Richter JA, Kahaleh M. Photodynamic therapy: Palliation and endoscopic technique in cholangiocarcinoma. *World J Gastrointest Endosc* 2010; 2(11): 357-361 Available from: URL: <http://www.wjgnet.com/1948-5190/full/v2/i11/357.htm> DOI: <http://dx.doi.org/10.4253/wjge.v2.i11.357>

INTRODUCTION

Cholangiocarcinoma is the primary neoplasia originating from the biliary system. The incidence rate is 1-2 per 100000 people per year in the United States^[1,2]. Initially thought to be an uncommon disease, the number of cases reported annually has been climbing^[2-4]. Nearly two-thirds of cases of cholangiocarcinoma occur in patients between the ages of 50 and 70, and the tumor appears to have a male predominance^[2,5]. Predisposing conditions include disorders such as primary sclerosing cholangitis, intrahepatic stones and choledocholithiasis, choledochal cysts, liver flukes, and previous exposure to the contrast agent thorium dioxide (Thorotrast)^[6-16].

Complete surgical resection is the only treatment with potential for a cure. Unfortunately, more than 50% of patients present with unresectable disease at the time of diagnosis^[17-19]. The prognosis at this stage is dismal, being approximately 3 mo without intervention, and 4-6 mo after palliative biliary decompression^[20-25]. Even after curative (RO) resection the 5-year survival rate is only 30%-40%^[26-28]. Successful palliation of biliary obstruction remains the main goal for reducing morbidity and mortality in these patients^[21,29].

PALLIATION OF CHOLANGIOCARCINOMA

The approach to biliary decompression has evolved from a surgical approach, to percutaneous drainage, and finally to endoscopic management. Hepaticojejunostomy is associated with a 30-d postoperative mortality rate of

between 7% and 24%^[30-34]. Furthermore, quality of life was only improved in a minority of patients undergoing surgery because of the time needed to recover^[24,35,36]. Biliary stenting only provides temporary relief^[37-42]. Adding chemotherapeutic agents has been largely unsuccessful; moreover, no standard chemotherapeutic regimen currently exists^[43]. Various chemotherapeutic agents have been studied, with limited improvement in survival rates^[44-46]. Radiotherapy is an area of great controversy regarding its efficacy in cholangiocarcinoma, and is associated with an increased incidence of cholangitis, gastro-duodenitis, and longer hospitalization^[47-49]. However, concurrent chemoradiotherapy with helical tomotherapy intensity modulated radiotherapy and capecitabine, in conjunction with photodynamic therapy, has been shown to be well tolerated in patients with hilar cholangiocarcinoma^[50,51].

PRINCIPLE OF PHOTODYNAMIC THERAPY

PDT is a two step process. during which a photosensitizer is initially administered, followed by photoradiation^[52]. Photofrin (porfimer sodium, Axcan Pharma Inc., Mont-Saint Hilaire, Canada) remains the most commonly used drug in this setting, since it has a selective nature and is preferentially retained by neoplastic tissue^[53]. Laser application at a specific wavelength starts the activation process by transforming the drug from its neutral ground state, into its activated state. In the presence of oxygen, cytotoxic singlet oxygen species are formed, destroying the dysplastic cells to which they are bound. These free radicals induce apoptosis and tumor necrosis to a depth of 4 mm to 6 mm^[54,55]. Synergistically, nearby vascular channels are also affected, indirectly accelerating the process by cutting off the supply of vital nutrients.

PDT has been shown to reduce xenografted human cholangiocarcinoma tumor volume by 60% in a mouse model^[56]. Recent reports and randomized controlled studies in which PDT was used as an adjuvant therapy, have shown a significant survival benefit in patients with unresectable cholangiocarcinoma, as well as a significant improvement in the quality of life after PDT and stenting^[57,58].

TECHNIQUES

The technique used to execute the procedure has become standardized. PDT has typically been offered to patients with nonresectable cholangiocarcinoma, or as a neoadjuvant therapy. Staging can be performed with computed tomography and/or magnetic resonance imaging^[58]. Resectability is usually defined according to the criteria of Vauthey and Blumgart^[59].

Each patient found to be a candidate for PDT undergoes a thorough educational process. Indeed, specific education regarding sun exposure and protection is necessary in order to avoid severe sun-related phototoxicity, and should be provided to all patients prior to the procedure^[58].

Endoscopic retrograde cholangiography (ERC) is performed using therapeutic duodenoscope (TJF-140, TJF-160, and TJF-160VF; Olympus America, Center Valley, PA). After cannulation into the biliary tract, a cholangiogram is performed to help define the anatomic distribution of malignant tissue and the extent of disease within the biliary ducts. Careful opacification of the dilated segments is realized selectively. Bougie and balloon dilation of the stricture(s) to be treated is performed, to facilitate diffuser placement within the malignant stricture.

After placement of the diffuser probe within the stricture to be treated, photoactivation is performed at 630 nm with a light dose of 180 J/cm², fluence of 0.250 W/cm² and irradiation time of 750 s. One or more segments can be treated at the discretion of the endoscopist. When tumor length exceeds the maximal diffuser length, step-wise pull-back of the fiber under fluoroscopic guidance can be done. Placement of an endoprosthesis is performed systematically after the photodynamic treatment to prevent cholangitis. Our group has recently demonstrated the safety and efficacy of choledochoscopy-guided PDT, allowing specific intraductal visualization of the stricture(s) to be treated^[59].

For patients failing conventional ERC, a technique for photodynamic therapy using percutaneous biliary access can be used, in which a percutaneous drain is replaced with an 8French vascular sheath over a guidewire^[60]. PDT is typically repeated at 3-mo intervals at which time all stents should be replaced. Stents are exchanged earlier in the case of premature occlusion or migration, to maintain optimal biliary drainage. All patients should receive perioperative antibiotic prophylaxis. Post-therapy, patients treated with PDT are advised to remain out of direct sunlight, since Porfimer sodium may cause prolonged photosensitivity lasting 30-90 d^[61].

ACCESSORIES

Though other photosensitizers are now available, porfimer sodium is the most studied, and the only photosensitizer approved by the FDA. It is administered intravenously at a dose of 2 mg/kg body weight 48 h prior to illumination. A diode laser system (InGaAlP Laser Diode; Diomed Inc., Andover, MA) with a maximum power output of 2000 mW and a wavelength of 630 nm is used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT). The diffuser can be inserted into a 10 F sheath of a plastic stent delivery system (MAJ-1419; Olympus America) and placed at the level of the stricture being treated. Alternatively, our group has been using the single operator choledochoscope (Spyglass, Boston Scientific, Natick, MA) as a platform to administer PDT^[59].

RESULTS AND OUTCOMES

There have been several reports suggesting that PDT provides a survival benefit (Table 1)^[52,58,61-66]. In 2003, Ort-

Table 1 Table comparing studies performed by using endoscopic retrograde cholangiopancreatography with photodynamic therapy with photofrin sodium for palliation of cholangiocarcinoma

Study	Year	N	Study type	Median TB before and after PDT	Mean PDT sessions (range)	Median survival (mo)	Adverse events phototoxicity, cholangitis n (%)
Ortner <i>et al</i> ^[62]	1998	9	Single Arm	18.6 > 6	1.5 (1-2)	14.6	1 (11), 0 (0)
Berr <i>et al</i> ^[62]	2000	23	Single Arm	11.2 > 1.1	3.0 (1-5)	11.1	3 (13), 8 (35)
Rumalia <i>et al</i> ^[63]	2001	6	Single Arm	2.7 > 1.3	2.3 (1-2)	> 6	2 (33), 2 (33)
Dumoulin <i>et al</i> ^[64]	2003	24	Single Arm	13.3 > 2.6	1-2	9.9	2 (8), 5 (21)
Ortner <i>et al</i> ^[52]	2003	20	Randomized	NA (decreased)	2.4 (1-5)	16.4	2 (10), 5 (25)
Ortner <i>et al</i> ^[52]	2003	31	Nonrandomized	11.8 > 3.1	1.5 (1-4)	14.2	3 (10), 6 (19)
Harewood <i>et al</i> ^[65]	2005	8	Single Arm	7.7 > 1.1	2.0 (1-5)	9.2	2 (25), 2 (25)
Witzigmann <i>et al</i> ^[66]	2006	68	Single Arm	NA (decreased)	2.0 (1-6)	12.0	8 (12), 38 (56)
Prasad <i>et al</i> ^[61]	2007	25	Single Arm	6.1 > 3.5	1.6 (1-4)	13.4	1 (4), 2 (8)
Kahaleh <i>et al</i> ^[58]	2008	19	Comparative	6.3 > 3.5	1.6 (1-3)	16.2	3 (16), 7 (37)

TB: total bilirubin; NA: not available; PDT: photodynamic therapy.

ner *et al*^[52] conducted the first randomized controlled trial comparing survival rates in patients treated with biliary stenting alone with those treated with biliary decompression combined with photodynamic therapy. After 39 patients were enrolled in the study, improvement in survival and quality of life in the randomized PDT group was found to be so impressive [i.e. 493 d ($n = 20$) *vs* a median survival of 98 d ($n = 19$), $P < 0.0001$] that the trial was terminated prematurely. However, only patients failing conventional ERC were enrolled in that trial, making a repeat ERC indispensable, which might account for the benefit attributed to PDT.

In 2007, the Mayo team demonstrated that patients with unresectable cholangiocarcinoma without a visible mass benefited from early treatment with PDT^[61]. In 2008, our group published findings comparing stenting alone with a combination therapy of stenting and photodynamic therapy^[58]. Kaplan-Meier analysis demonstrated improved survival in the PDT group compared with the stent-alone group (16.2 *vs* 7.4 mo, $P < 0.004$). Mortality in the PDT group at 3, 6, and 12 mo was 0%, 16%, and 56% respectively. The corresponding mortality in the stent group was 28%, 52%, and 82% respectively. The difference between the two groups was statistically significant at 3 and 6 mo, but not at 12 mo. Although it was not entirely clear whether the benefit was directly related to PDT or the number of endoscopic retrograde cholangiopancreatography sessions, this study helped to strengthen the findings published by Ortner *et al*^[52] in 2003. Furthermore, adverse effects in the PDT group were minor, and largely related to mild phototoxicity managed conservatively. Other complications included cholangitis, hemobilia, cholecystitis, pancreatitis, duodenal perforation, hepatic abscess and myocardial infarction, and were a result of the endoscopic procedure and found in both groups treated^[57].

Recently, Wiedmann *et al*^[67] published their results using PDT as a neoadjuvant treatment for hilar cholangiocarcinoma. Seven patients were treated and underwent surgery after a median period of 6 wk (range, 3-44 wk). In all patients, tumor free resection margins were achieved with a 1-year recurrence free survival rate of 83%. Neoa-

djuvant PDT did not increase the rate of surgical complications and was well tolerated.

If PDT has become a standard of care in Europe, novel therapeutic approaches are still needed, such as a targeted molecular approach that may be used in conjunction to improve outcomes. For this therapy to become a more viable option alternative, photosensitizers are needed that provide deeper tumoricidal tissue penetration, shorter duration of phototoxicity, and more rapid onset^[68].

CONCLUSION

In summary, the majority of patients with cholangiocarcinoma present with advanced, unresectable disease and treatment options remain limited. Photodynamic therapy in conjunction with stenting has shown very promising outcomes. Further multicenter, randomized, prospective controlled trials are needed to confirm the benefit of PDT and stenting compared to stenting alone, and to identify the optimal treatment regimen in these patients in order to improve their survival and quality of life.

REFERENCES

- 1 Callery MR, Meyers WC: Bile Duct Cancer. In Cameron JL (ed): Current Surgical Therapy, 6th ed. Baltimore, Mosby, 1998; 455
- 2 Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. *Semin Liver Dis* 2004; **24**: 115-125
- 3 Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. *J Hepatol* 2002; **37**: 806-813
- 4 Patel T. Worldwide trends in mortality from biliary tract malignancies. *BMC Cancer* 2002; **2**: 108
- 5 Burgos San Juan L. [Cholangiocarcinoma]. *Rev Med Chil* 2008; **136**: 240-248
- 6 Bergquist A, Broomé U. Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis. *Best Pract Res Clin Gastroenterol* 2001; **15**: 643-656
- 7 Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Lööf L, Danielsson A, Hultcrantz R, Lindgren S, Prytz H, Sandberg-Gertzén H, Almer S, Granath F, Broomé U. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. *J Hepatol* 2002; **36**: 321-327
- 8 Haswell-Elkins MR, Mairiang E, Mairiang P, Chaiyakum

- J, Chamadol N, Loapaiboon V, Sithithaworn P, Elkins DB. Cross-sectional study of *Opisthorchis viverrini* infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. *Int J Cancer* 1994; **59**: 505-509
- 9 **Jang KT**, Hong SM, Lee KT, Lee JG, Choi SH, Heo JS, Choi DW, Choi D, Lim JH. Intraductal papillary neoplasm of the bile duct associated with *Clonorchis sinensis* infection. *Virchows Arch* 2008; **453**: 589-598
- 10 **Kubo S**, Kinoshita H, Hirohashi K, Hamba H. Hepatolithiasis associated with cholangiocarcinoma. *World J Surg* 1995; **19**: 637-641
- 11 **Lesurtel M**, Regimbeau JM, Farges O, Colombat M, Sauvanet A, Belghiti J. Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries. *Eur J Gastroenterol Hepatol* 2002; **14**: 1025-1027
- 12 **Chu KM**, Lo CM, Liu CL, Fan ST. Malignancy associated with hepatolithiasis. *Hepatogastroenterology* 1997; **44**: 352-357
- 13 **Kim YT**, Byun JS, Kim J, Jang YH, Lee WJ, Ryu JK, Kim SW, Yoon YB, Kim CY. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. *Hepatogastroenterology* 2003; **50**: 8-12
- 14 **Chapman RW**. Risk factors for biliary tract carcinogenesis. *Ann Oncol* 1999; **10** Suppl 4: 308-311
- 15 **Lawrence R**, Rubel, Kamal G, Ishak. Thorotrast-associated cholangiocarcinoma. *Cancer* 1982; **50**: 1408-1415
- 16 **Khan SA**, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. *Lancet* 2005; **366**: 1303-1314
- 17 **de Groen PC**, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. *N Engl J Med* 1999; **341**: 1368-1378
- 18 **Jarnagin WR**, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. *Ann Surg* 2001; **234**: 507-517; discussion 517-519
- 19 **Reed DN Jr**, Vitale GC, Martin R, Bas H, Wieman TJ, Larson GM, Edwards M, McMasters K. Bile duct carcinoma: trends in treatment in the nineties. *Am Surg* 2000; **66**: 711-714; discussion 714-715
- 20 **Liu CL**, Lo CM, Lai EC, Fan ST. Endoscopic retrograde cholangiopancreatography and endoscopic endoprosthesis insertion in patients with Klatskin tumors. *Arch Surg* 1998; **133**: 293-296
- 21 **Polydorou AA**, Cairns SR, Dowsett JF, Hatfield AR, Salmon PR, Cotton PB, Russell RC. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion. *Gut* 1991; **32**: 685-689
- 22 **Ducreux M**, Liguory C, Lefebvre JF, Ink O, Choury A, Fritsch J, Bonnel D, Derhy S, Etienne JP. Management of malignant hilar biliary obstruction by endoscopy. Results and prognostic factors. *Dig Dis Sci* 1992; **37**: 778-783
- 23 **Farley DR**, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after non-curative intervention. *Mayo Clin Proc* 1995; **70**: 425-429
- 24 **Baer HU**, Stain SC, Dennison AR, Eggers B, Blumgart LH. Improvements in survival by aggressive resections of hilar cholangiocarcinoma. *Ann Surg* 1993; **217**: 20-27
- 25 **Devieere J**, Baize M, de Toeuf J, Cremer M. Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage. *Gastrointest Endosc* 1988; **34**: 95-101
- 26 **Lazaridis KN**, Gores GJ. Cholangiocarcinoma. *Gastroenterology* 2005; **128**: 1655-1667
- 27 **Jarnagin WR**, Shoup M. Surgical management of cholangiocarcinoma. *Semin Liver Dis* 2004; **24**: 189-199
- 28 **Neuhaus P**, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, Wex C, Lobeck H, Hintze R. Extended resections for hilar cholangiocarcinoma. *Ann Surg* 1999; **230**: 808-818; discussion 819
- 29 **Gibson RN**, Yeung E, Hadjis N, Adam A, Benjamin IS, Allison DJ, Blumgart LH. Percutaneous transhepatic endoprotheses for hilar cholangiocarcinoma. *Am J Surg* 1988; **156**: 363-367
- 30 **Lai EC**, Tompkins RK, Mann LL, Roslyn JJ. Proximal bile duct cancer. Quality of survival. *Ann Surg* 1987; **205**: 111-118
- 31 **Havlik R**, Sbisà E, Tullio A, Kelly MD, Mitry RR, Jiao LR, Mansour MR, Honda K, Habib NA. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. *Hepatogastroenterology* 2000; **47**: 927-931
- 32 **Kapoor VK**, Pradeep R, Haribhakti SP, Singh V, Sikora SS, Saxena R, Kaushik SP. Intrahepatic segment III cholangiojejunostomy in advanced carcinoma of the gallbladder. *Br J Surg* 1996; **83**: 1709-1711
- 33 **Chaudhary A**, Dhar P, Tomey S, Sachdev A, Agarwal A. Segment III cholangiojejunostomy for carcinoma of the gallbladder. *World J Surg* 1997; **21**: 866-870; discussion 870-871
- 34 **Guthrie CM**, Banting SW, Garden OJ, Carter DC. Segment III cholangiojejunostomy for palliation of malignant hilar obstruction. *Br J Surg* 1994; **81**: 1639-1641
- 35 **Figueras J**, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, Rafecas A, Torras J, Jaurrieta E. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. *Liver Transpl* 2000; **6**: 786-794
- 36 **Blom D**, Schwartz SI. Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. *Arch Surg* 2001; **136**: 209-215
- 37 **Smith AC**, Dowsett JF, Russell RC, Hatfield AR, Cotton PB. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. *Lancet* 1994; **344**: 1655-1660
- 38 **Daivids PH**, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. *Lancet* 1992; **340**: 1488-1492
- 39 **Schmassmann A**, von Gunten E, Knuchel J, Scheurer U, Fehr HF, Halter F. Wallstents versus plastic stents in malignant biliary obstruction: effects of stent patency of the first and second stent on patient compliance and survival. *Am J Gastroenterol* 1996; **91**: 654-659
- 40 **Born P**, Rösch T, Brühl K, Sandschin W, Weigert N, Ott R, Frimberger E, Allescher HD, Hoffmann W, Neuhaus H, Classen M. Long-term outcome in patients with advanced hilar bile duct tumors undergoing palliative endoscopic or percutaneous drainage. *Z Gastroenterol* 2000; **38**: 483-489
- 41 **Peters RA**, Williams SG, Lombard M, Karani J, Westaby D. The management of high-grade hilar strictures by endoscopic insertion of self-expanding metal endoprotheses. *Endoscopy* 1997; **29**: 10-16
- 42 **Prat F**, Chapat O, Ducot B, Ponchon T, Pelletier G, Fritsch J, Choury AD, Buffet C. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. *Gastrointest Endosc* 1998; **47**: 1-7
- 43 **van Groeningen CJ**. Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer. *Ann Oncol* 1999; **10** Suppl 4: 305-307
- 44 **Choi CW**, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. *Am J Clin Oncol* 2000; **23**: 425-428
- 45 **Patt YZ**, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. *J Clin Oncol* 1996; **14**: 2311-2315
- 46 **Ducreux M**, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. *Ann Oncol* 1998; **9**: 653-656
- 47 **Bowling TE**, Galbraith SM, Hatfield AR, Solano J, Spittle MF. A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma. *Gut* 1996; **39**: 852-855
- 48 **Ayaru L**, Bown SG, Pereira SP. Photodynamic therapy for

- pancreatic and biliary tract carcinoma. *Int J Gastrointest Cancer* 2005; **35**: 1-13
- 49 **Khan SA**, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. *Gut* 2002; **51** Suppl 6: VI1-VI9
- 50 **Baisden JM**, Kahaleh M, Weiss GR, Sanfey H, Moskaluk CA, Yeaton P, de Lange EE, Rich TA. Multimodality Treatment With Helical Tomotherapy Intensity Modulated Radiotherapy, Capecitabine, and Photodynamic Therapy is Feasible and Well Tolerated in Patients With Hilar Cholangiocarcinoma. *Gastrointest Cancer Res* 2008; **2**: 219-224
- 51 **Thongprasert S**. The role of chemotherapy in cholangiocarcinoma. *Ann Oncol* 2005; **16** Suppl 2: ii93-ii96
- 52 **Ortner ME**, Caca K, Berr F, Liebetruh J, Mansmann U, Huster D, Voderholzer W, Schachschal G, Mössner J, Lochs H. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. *Gastroenterology* 2003; **125**: 1355-1363
- 53 **Giuliano EA**, Ota J, Tucker SA. Photodynamic therapy: basic principles and potential uses for the veterinary ophthalmologist. *Vet Ophthalmol* 2007; **10**: 337-343
- 54 **Henderson BW**, Waldow SM, Mang TS, Potter WR, Malone PB, Dougherty TJ. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. *Cancer Res* 1985; **45**: 572-576
- 55 **Wong Kee Song LM**, Wang KK, Zinsmeister AR. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. *Cancer* 1998; **82**: 421-427
- 56 **Berr F**, Wiedmann M, Tannapfel A, Halm U, Kohlhaw KR, Schmidt F, Wittekind C, Hauss J, Mössner J. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. *Hepatology* 2000; **31**: 291-298
- 57 **Zoepf T**, Jakobs R, Arnold JC, Apel D, Riemann JF. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. *Am J Gastroenterol* 2005; **100**: 2426-2230
- 58 **Kahaleh M**, Mishra R, Shami VM, Northup PG, Berg CL, Bashlor P, Jones P, Ellen K, Weiss GR, Brenin CM, Kurth BE, Rich TA, Adams RB, Yeaton P. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. *Clin Gastroenterol Hepatol* 2008; **6**: 290-297
- 59 **Talreja JP**, Sauer B, Ellen K, Rehan ME, Shami VM, Kahaleh M. Photodynamic Therapy for Unresectable Cholangiocarcinoma: What Is the Contribution of Single Operator Cholangioscopy for Targeted Treatment? *Gastrointest Endosc* 2009; **69**: AB146
- 60 **Vauthey JN**, Blumgart LH. Recent advances in the management of cholangiocarcinomas. *Semin Liver Dis* 1994; **14**: 109-114
- 61 **Prasad GA**, Wang KK, Baron TH, Buttar NS, Wongkeesong LM, Roberts LR, LeRoy AJ, Lutzke LS, Borkenhagen LS. Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. *Clin Gastroenterol Hepatol* 2007; **5**: 743-748
- 62 **Ortner MA**, Liebetruh J, Schreiber S, Hanft M, Wruck U, Fusco V, Müller JM, Hörtnagl H, Lochs H. Photodynamic therapy of nonresectable cholangiocarcinoma. *Gastroenterology* 1998; **114**: 536-542
- 63 **Rumalla A**, Baron TH, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Endoscopic application of photodynamic therapy for cholangiocarcinoma. *Gastrointest Endosc* 2001; **53**: 500-504
- 64 **Dumoulin FL**, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, Sauerbruch T. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. *Gastrointest Endosc* 2003; **57**: 860-867
- 65 **Harewood GC**, Baron TH, Rumalla A, Wang KK, Gores GJ, Stadheim LM, de Groen PC. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. *J Gastroenterol Hepatol* 2005; **20**: 415-420
- 66 **Witzigmann H**, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, Tannapfel A, Wittekind C, Mossner J, Hauss J, Wiedmann M. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. *Ann Surg* 2006; **244**: 230-239
- 67 **Wiedmann M**, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, Mössner J, Hauss J, Witzigmann H. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. *Cancer* 2003; **97**: 2783-2790
- 68 **Baron TH**. Photodynamic therapy: standard of care for palliation of cholangiocarcinoma? *Clin Gastroenterol Hepatol* 2008; **6**: 266-267

S- Editor Zhang HN L- Editor Herholdt A E- Editor Liu N